.svg){kind=icon}
.svg){kind=icon}
%201.svg){kind=icon}
%201.svg){kind=icon}
.svg){kind=icon}
.svg)
.svg)
Aparna Mathur
Aparna Mathur is a Senior Economist at White House Council of Economic Advisers. Prior to this she was a resident scholar in economic policy studies at the American Enterprise Institute (AEI), where she researches income inequality and mobility, tax policy, labour markets, and small businesses. She also directs the AEI-Brookings Project on Paid Family and Medical Leave, for which she was recognised in the 2017 Politico 50 list. Before joining AEI, Dr. Mathur was an instructor in economics at the University of Maryland. She has been also an adjunct professor at Georgetown University’s School of Public Policy (now the McCourt School of Public Policy).
The holder of a Ph.D. in economics from the University of Maryland, College Park, Dr. Mathur also has an M.A. in economics from the Delhi School of Economics (DSE) and a B.A. from Hindu College at Delhi University in India.
.svg)
Drug quality and global trade
There is a perception amongst pharmaceutical experts that some Indian manufacturers and/or their distributors segment the global medicine market into portions that are served by different quality medicines. This column finds that drug quality is poorer among Indian-labelled drugs purchased in African countries than among those purchased in India or middle-income countries. Substandard drugs – non-registered in Africa and containing insufficient amounts of the active ingredient – are the biggest driver of this quality difference.
